Fostemsavir

Fostemsavir
Names
	IUPAC name {3-[(4-Benzoyl-1-piperazinyl)(oxo)acetyl]-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl}methyl dihydrogen phosphate
	Other names BMS-663068, GSK3684934
Identifiers
CAS Number	864953-29-7;
3D model (JSmol)	Interactive image;
ChemSpider	9494181;
KEGG	D10707 ;
PubChem CID	11319217;
CompTox Dashboard (EPA)	DTXSID40235596 ;
	InChI InChI=1S/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38) Key: SWMDAPWAQQTBOG-UHFFFAOYSA-N; InChI=1/C25H26N7O8P/c1-16-27-14-32(28-16)23-21-20(19(39-2)12-26-23)18(13-31(21)15-40-41(36,37)38)22(33)25(35)30-10-8-29(9-11-30)24(34)17-6-4-3-5-7-17/h3-7,12-14H,8-11,15H2,1-2H3,(H2,36,37,38) Key: SWMDAPWAQQTBOG-UHFFFAOYAP;
	SMILES O=C(c1ccccc1)N5CCN(C(=O)C(=O)c4c2c(c(ncc2OC)n3nc(nc3)C)n(c4)COP(=O)(O)O)CC5;
Properties
Chemical formula	C25H26N7O8P
Molar mass	583.498 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Fostemsavir (GSK3684934/BMS-663068) is an experimental HIV entry inhibitor and a prodrug of temsavir (BMS-626529). It is under development by [ViiV Healthcare / GlaxoSmithKline]] for use in the treatment of HIV infection. By blocking the gp120 receptor of the virus, it prevents initial viral attachment to the host CD4+ T cell and entry into the host immune cell; its method of action is a first for HIV drugs.^[1] Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other HIV drugs.^[2] Since gp120 is a highly conserved area of the virus, the drug is unlikely to promote resistance to itself via generation of CD4-independent virus.^[3]

References

[1] HIV Attachment Inhibitor BMS-663068 Looks Good in Early Studies

[2] HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study

[3] Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors

[1]

[2]

[3]